Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-1
US7709214B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 20, 2007 |
| Grant date | May 4, 2010 |
| Priority date | — |
| Expiry date | Jun 20, 2027 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.